RNS26 Sep 2024 09:26
no more depressing than expected. the usual bull**** from the smoke and mirrors man. eg the quote below:
"angle has proactively re-shaped its business, focusing its best-in-class liquid biopsy solution to meet large pharma business needs. "
this is nonsense ; agl were forced to change tack when they realised that clinical delivery (direct to hospitals for patient use) was never going to happen given the state of clinical and therapeutic research at the time. so massive retrenchment had to go on, while a new approach was developed. to suggest that this was proactive is, to be polite, more hype from an. this has involved working with big pharma, so far with limited success, and also cosying up to illumina to share some of the attractions of analysing ctdna.
there is a very long road ahead.
meanwhile, why no inciteful comment from our resident guru, the carrot?